Journal Mobile Options
Table of Contents
Vol. 51, No. 1, 2014
Issue release date: December 2013
Section title: Original Paper
Ophthalmic Res 2014;51:1-8
(DOI:10.1159/000354328)

VEGF Gene Polymorphism and Response to Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration

dos Reis Veloso C.E. · Frota de Almeida L.N. · Recchia F.M. · Pelayes D. · Nehemy M.B.
aDepartment of Ophthalmology, Federal University of Minas Gerais, Belo Horizonte, Brazil; bVanderbilt Eye Institute, Nashville, Tenn., USA; cDepartment of Ophthalmology, Buenos Aires University, Buenos Aires, Argentina

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 6/3/2013 8:24:46 AM
Accepted: 7/8/2013
Published online: 10/22/2013

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 3

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: http://www.karger.com/ORE

Abstract

Background/Aims: To investigate the association between VEGF gene polymorphism and response to ranibizumab in neovascular age-related macular degeneration (AMD). Methods: A total of 92 patients were genotyped for the VEGF rs1413711 single nucleotide polymorphism. Patients with neovascular AMD initially received 3 monthly ranibizumab intravitreal injections and were retreated as needed. Visual acuity (VA) and central retinal thickness (CRT) were measured before and 1, 3, 6 and 12 months after treatment. Results: For patients with TT and CT genotypes, paired comparisons of mean VA showed improvement when the data obtained at all visits were compared with baseline values, in contrast to patients with the CC genotype. CRT statistically improved at all visits for all genotypes. Conclusion: Patients with the CC genotype showed poorer long-term functional and anatomical response to anti-VEGF therapy.


  

Author Contacts

Carlos Eduardo dos Reis Veloso
Rua dos Otoni 881, 13o andar, Santa Efigênia
Belo Horizonte, MG 30150-270 (Brazil)
E-Mail cerveloso@hotmail.com

  

Article Information

Received: June 3, 2013
Accepted: July 7, 2013
Published online: October 22, 2013
Number of Print Pages : 8
Number of Figures : 0, Number of Tables : 3, Number of References : 43

  

Publication Details

Ophthalmic Research (Journal for Research in Experimental and Clinical Ophthalmology)

Vol. 51, No. 1, Year 2014 (Cover Date: December 2013)

Journal Editor: Corcóstegui B. (Barcelona), Pelayes D.E. (Buenos Aires), Pleyer U. (Berlin)
ISSN: 0030-3747 (Print), eISSN: 1423-0259 (Online)

For additional information: http://www.karger.com/ORE


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 6/3/2013 8:24:46 AM
Accepted: 7/8/2013
Published online: 10/22/2013

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 3

ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)

For additional information: http://www.karger.com/ORE


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.